ReNeuron beefs up management as overseas ambitions grow

Stem cell therapy specialist ReNeuron (LON:RENE) has strengthened its middle management with two new appointments. Dr Julian Howell joins as Chief Medical Officer to oversee clinical development activities. A specialist in bringing small molecules and biological products through all phases of clinical development, he joins from Shield Therapeutics, where he was Group Medical Director. Shaun Stapleton has been appointed as Head of Regulatory Affairs and joins from Voisin Consulting arm RRG, where he was a Director and Vice President of Regulatory Science. Olav Hellebø, ReNeuron’s chief executive, said the two new appointees’ experience and knowledge of the industry would be major assets as the company increases its clinical development activities internationally. ReNeuron recently had its stem cell treatment for a group of rare eye diseases granted fast-track status by the US Food and Drug Administration. In April, the company also received encouraging results from Phase I of a trial for a stem cell treatment for disabled stroke patients.